Hamps Bio Limited
₹ 24.0
-2.00%
05 Dec
- close price
About
Incorporated in 2007, Hamps Bio Ltd is in the business of Pharmaceutical Formulation and Freeze-Drying Ingredient Manufacturing and Distribution[1]
Key Points
- Market Cap ₹ 20.9 Cr.
- Current Price ₹ 24.0
- High / Low ₹ 53.6 / 17.1
- Stock P/E
- Book Value ₹ 9.76
- Dividend Yield 0.00 %
- ROCE 6.68 %
- ROE 4.94 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 12.1% over last 3 years.
- Company might be capitalizing the interest cost
- Working capital days have increased from 40.4 days to 124 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 5.34 | 5.58 | 6.48 | 6.67 | 7.12 | |
| 4.72 | 4.71 | 5.31 | 5.90 | 6.72 | |
| Operating Profit | 0.62 | 0.87 | 1.17 | 0.77 | 0.40 |
| OPM % | 11.61% | 15.59% | 18.06% | 11.54% | 5.62% |
| 0.00 | 0.01 | 0.03 | 0.15 | 0.11 | |
| Interest | 0.19 | 0.18 | 0.15 | 0.14 | 0.17 |
| Depreciation | 0.33 | 0.34 | 0.40 | 0.38 | 0.49 |
| Profit before tax | 0.10 | 0.36 | 0.65 | 0.40 | -0.15 |
| Tax % | -20.00% | 0.00% | 23.08% | 25.00% | |
| 0.12 | 0.36 | 0.50 | 0.30 | -0.17 | |
| EPS in Rs | 0.40 | 1.20 | 1.28 | 0.34 | -0.20 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 36% |
| TTM: | -134% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1.50 | 1.50 | 1.96 | 4.36 | 8.71 |
| Reserves | -0.49 | -0.14 | 1.38 | 4.44 | -0.21 |
| 2.04 | 1.74 | 1.05 | 2.97 | 3.74 | |
| 0.60 | 0.86 | 0.73 | 0.97 | 0.95 | |
| Total Liabilities | 3.65 | 3.96 | 5.12 | 12.74 | 13.19 |
| 2.15 | 2.61 | 2.52 | 2.43 | 3.92 | |
| CWIP | 0.00 | 0.00 | 0.00 | 3.38 | 3.39 |
| Investments | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| 1.46 | 1.35 | 2.60 | 6.93 | 5.88 | |
| Total Assets | 3.65 | 3.96 | 5.12 | 12.74 | 13.19 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0.33 | 1.23 | -0.29 | -1.77 | |
| 0.51 | -0.75 | -0.37 | -6.20 | |
| -0.94 | -0.48 | 0.67 | 8.00 | |
| Net Cash Flow | -0.10 | 0.00 | 0.01 | 0.04 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 47.16 | 49.71 | 55.76 | 65.12 |
| Inventory Days | 94.57 | 75.03 | 264.09 | 452.45 |
| Days Payable | 63.05 | 103.42 | 60.12 | 114.06 |
| Cash Conversion Cycle | 78.69 | 21.32 | 259.73 | 403.51 |
| Working Capital Days | -34.86 | -58.22 | 55.20 | 124.22 |
| ROCE % | 17.56% | 21.36% | 6.68% |
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
25 Nov - EGM approved Ms. Shivali Rajpurohit as independent director unanimously on 24 Nov 2025.
-
Shareholder Meeting / Postal Ballot-Outcome of EGM
24 Nov - EGM on 24-Nov-2025 regularized Ms. Shivali Rajpurohit as independent director.
-
Unaudited Financial Results For The Half Year Ended 30.09.2025.
14 Nov - Board approved unaudited half-year results ended 30 Sep 2025; limited review attached.
-
Board Meeting Outcome for Board Meeting Outcome For Approval Of Unaudited Financial Results For The Half Year Ended 30.09.2025
14 Nov - Approved unaudited H1 results for period ended 30 Sep 2025; limited review attached.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Half Year Ended September 30, 2025
13 Nov - Board meeting rescheduled to Nov 14, 2025 to consider unaudited results for half-year ended Sep 30, 2025.
Business Overview:[1]
HBL is in the business of ethical marketing and distribution of pharmaceutical formulations across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine & nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers.